A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice

Respiratory Research

Volumn 11, Issue , 2010, Pages

  Zhu, Yuanjue ^a   Liu, Yong ^a   Zhou, Weixun ^a   Xiang, Ruolan ^b   Jiang, Lei ^a   Huang, Kewu ^c   Xiao, Yu ^a   Guo, Zijian ^a   Gao, Jinming ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYDROXYPROLINE; ILOPROST; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; AUTACOID; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; INFLAMMATION; INFLAMMATORY CELL; LUNG COMPLIANCE; LUNG FIBROSIS; LUNG LAVAGE; LUNG MECHANICS; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; GENETICS; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PNEUMONIA; TIME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACID; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HYDROXYPROLINE; ILOPROST; INFLAMMATION MEDIATORS; INJECTIONS, INTRAPERITONEAL; LUNG; LUNG COMPLIANCE; MALE; MICE; MICE, INBRED C57BL; PNEUMONIA; PULMONARY FIBROSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; WEIGHT LOSS;

EID: 77954573839     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-11-34     Document Type: Article

References (45)

1. American thoracic society. Idiopathic pulmonary fibrosis Diagnosis and treatment. International consensus statement. American thoracic society (ats), and the european respiratory society (ers). American journal of respiratory and critical care medicine 2000, 161(2 Pt 1):646-664. American thoracic society. Idiopathic pulmonary fibrosis.
2. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001, 120(2):617-624. 10.1378/chest.120.2.617, 11502668.
3. Huang SK, Peters-Golden M. Eicosanoid lipid mediators in fibrotic lung diseases: Ready for prime time?. Chest 2008, 133(6):1442-1450. 10.1378/chest.08-0306, 2582216, 18574287.
4. Wardlaw AJ, Hay H, Cromwell O, Collins JV, Kay AB. Leukotrienes, ltc4 and ltb4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. The Journal of allergy and clinical immunology 1989, 84(1):19-26. 10.1016/0091-6749(89)90173-5, 2546985.
5. Peters-Golden M, Bailie M, Marshall T, Wilke C, Phan SH, Toews GB, Moore BB. Protection from pulmonary fibrosis in leukotriene-deficient mice. American journal of respiratory and critical care medicine 2002, 165(2):229-235.
6. Izumo T, Kondo M, Nagai A. Effects of a leukotriene b4 receptor antagonist on bleomycin-induced pulmonary fibrosis. Eur Respir J 2009,
7. Huang SK, Wettlaufer SH, Hogaboam CM, Flaherty KR, Martinez FJ, Myers JL, Colby TV, Travis WD, Toews GB, Peters-Golden M. Variable prostaglandin e2 resistance in fibroblasts from patients with usual interstitial pneumonia. American journal of respiratory and critical care medicine 2008, 177(1):66-74. 10.1164/rccm.200706-963OC, 2176116, 17916807.
8. Failla M, Genovese T, Mazzon E, Fruciano M, Fagone E, Gili E, Barera A, La Rosa C, Conte E, Crimi N, et al. 16,16-dimethyl prostaglandin e2 efficacy on prevention and protection from bleomycin-induced lung injury and fibrosis. American journal of respiratory cell and molecular biology 2009, 41(1):50-58. 10.1165/rcmb.2007-0438OC, 19059888.
9. Soberman RJ, Christmas P. Revisiting prostacyclin: New directions in pulmonary fibrosis and inflammation. American journal of physiology 2006, 291(2):L142-143.
10. Cruz-Gervis R, Stecenko AA, Dworski R, Lane KB, Loyd JE, Pierson R, King G, Brigham KL. Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis. Respiratory research 2002, 3:17. 10.1186/rr166, 107846, 11980586.
11. Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T, Martin GR, Black CM, Abraham D. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. The Journal of clinical investigation 2001, 108(2):241-250. 203022, 11457877.
12. Kohyama T, Liu X, Kim HJ, Kobayashi T, Ertl RF, Wen FQ, Takizawa H, Rennard SI. Prostacyclin analogs inhibit fibroblast migration. American journal of physiology 2002, 283(2):L428-432.
13. Lovgren AK, Jania LA, Hartney JM, Parsons KK, Audoly LP, Fitzgerald GA, Tilley SL, Koller BH. Cox-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. American journal of physiology 2006, 291(2):L144-156.
14. Murakami S, Nagaya N, Itoh T, Kataoka M, Iwase T, Horio T, Miyahara Y, Sakai Y, Kangawa K, Kimura H. Prostacyclin agonist with thromboxane synthase inhibitory activity (ono-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. American journal of physiology 2006, 290(1):L59-65.
15. Idzko M, Hammad H, van Nimwegen M, Kool M, Vos N, Hoogsteden HC, Lambrecht BN. Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. The Journal of clinical investigation 2007, 117(2):464-472. 10.1172/JCI28949, 1783814, 17273558.
16. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. Journal of clinical pathology 1988, 41(4):467-470. 10.1136/jcp.41.4.467, 1141479, 3366935.
17. Beller TC, Friend DS, Maekawa A, Lam BK, Austen KF, Kanaoka Y. Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(9):3047-3052. 10.1073/pnas.0400235101, 365742, 14970333.
18. Card JW, Voltz JW, Carey MA, Bradbury JA, Degraff LM, Lih FB, Bonner JC, Morgan DL, Flake GP, Zeldin DC. Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis. American journal of respiratory cell and molecular biology 2007, 37(3):300-308. 10.1165/rcmb.2007-0057OC, 1994226,1994226, 17496151.
19. Nagase T, Uozumi N, Ishii S, Kita Y, Yamamoto H, Ohga E, Ouchi Y, Shimizu T. A pivotal role of cytosolic phospholipase a(2) in bleomycin-induced pulmonary fibrosis. Nature medicine 2002, 8(5):480-484. 10.1038/nm0502-480, 11984592.
20. Nie L, Xiang R, Zhou W, Lu B, Cheng D, Gao J. Attenuation of acute lung inflammation induced by cigarette smoke in cxcr3 knockout mice. Respiratory research 2008, 9:82. 10.1186/1465-9921-9-82, 2654035, 19087279.
21. Moore BB, Paine R, Christensen PJ, Moore TA, Sitterding S, Ngan R, Wilke CA, Kuziel WA, Toews GB. Protection from pulmonary fibrosis in the absence of ccr2 signaling. J Immunol 2001, 167(8):4368-4377.
22. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. American journal of physiology 2008, 294(2):L152-160.
23. Arras M, Louahed J, Simoen V, Barbarin V, Misson P, Brule S, Delos M, Knoops L, Renauld JC, Lison D, et al. B lymphocytes are critical for lung fibrosis control and prostaglandin e2 regulation in il-9 transgenic mice. American journal of respiratory cell and molecular biology 2006, 34(5):573-580. 10.1165/rcmb.2004-0383OC, 16424385.
24. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. The Journal of experimental medicine 1989, 170(3):655-663. 10.1084/jem.170.3.655, 2189418, 2475571.
25. Piguet PF, Collart MA, Grau GE, Sappino AP, Vassalli P. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature 1990, 344(6263):245-247. 10.1038/344245a0, 2156165.
26. Zhou W, Hashimoto K, Goleniewska K, O'Neal JF, Ji S, Blackwell TS, Fitzgerald GA, Egan KM, Geraci MW, Peebles RS. Prostaglandin i2 analogs inhibit proinflammatory cytokine production and t cell stimulatory function of dendritic cells. J Immunol 2007, 178(2):702-710.
27. Yoshida M, Sakuma J, Hayashi S, Abe K, Saito I, Harada S, Sakatani M, Yamamoto S, Matsumoto N, Kaneda Y, et al. A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor b gene. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(21):9570-9574. 10.1073/pnas.92.21.9570, 40843, 7568174.
28. Saito F, Tasaka S, Inoue K, Miyamoto K, Nakano Y, Ogawa Y, Yamada W, Shiraishi Y, Hasegawa N, Fujishima S, et al. Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. American journal of respiratory cell and molecular biology 2008, 38(5):566-571. 10.1165/rcmb.2007-0299OC, 18096870.
29. Lee CG, Kang HR, Homer RJ, Chupp G, Elias JA. Transgenic modeling of transforming growth factor-beta(1): Role of apoptosis in fibrosis and alveolar remodeling. Proceedings of the American Thoracic Society 2006, 3(5):418-423. 10.1513/pats.200602-017AW, 2658706, 16799085.
30. Bartram U, Speer CP. The role of transforming growth factor beta in lung development and disease. Chest 2004, 125(2):754-765. 10.1378/chest.125.2.754, 14769761.
31. Bergeron A, Soler P, Kambouchner M, Loiseau P, Milleron B, Valeyre D, Hance AJ, Tazi A. Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for tgf-beta and il-10. Eur Respir J 2003, 22(1):69-76. 10.1183/09031936.03.00014703, 12882453.
32. Khalil N, O'Connor RN, Flanders KC, Unruh H. Tgf-beta 1, but not tgf-beta 2 or tgf-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: An immunohistochemical study. American journal of respiratory cell and molecular biology 1996, 14(2):131-138.
33. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. The Journal of clinical investigation 1997, 100(4):768-776. 10.1172/JCI119590, 508247, 9259574.
34. Zhang XL, Topley N, Ito T, Phillips A. Interleukin-6 regulation of transforming growth factor (tgf)-beta receptor compartmentalization and turnover enhances tgf-beta1 signaling. The Journal of biological chemistry 2005, 280(13):12239-12245. 10.1074/jbc.M413284200, 15661740.
35. Segel MJ, Izbicki G, Cohen PY, Or R, Christensen TG, Wallach-Dayan SB, Breuer R. Role of interferon-gamma in the evolution of murine bleomycin lung fibrosis. American journal of physiology 2003, 285(6):L1255-1262.
36. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. The New England journal of medicine 1999, 341(17):1264-1269. 10.1056/NEJM199910213411703, 10528036.
37. Jiang D, Liang J, Hodge J, Lu B, Zhu Z, Yu S, Fan J, Gao Y, Yin Z, Homer R, et al. Regulation of pulmonary fibrosis by chemokine receptor cxcr3. The Journal of clinical investigation 2004, 114(2):291-299. 449741, 15254596.
38. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/smad signalling by the interferon-gamma/stat pathway. Nature 1999, 397(6721):710-713. 10.1038/17826, 10067896.
39. Strieter RM, Starko KM, Enelow RI, Noth I, Valentine VG. Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine 2004, 170(2):133-140. 10.1164/rccm.200312-1670OC, 15044205.
40. Strieter RM, Gomperts BN, Keane MP. The role of cxc chemokines in pulmonary fibrosis. The Journal of clinical investigation 2007, 117(3):549-556. 10.1172/JCI30562, 1804376, 17332882.
41. Tager AM, Kradin RL, LaCamera P, Bercury SD, Campanella GS, Leary CP, Polosukhin V, Zhao LH, Sakamoto H, Blackwell TS, et al. Inhibition of pulmonary fibrosis by the chemokine ip-10/cxcl10. American journal of respiratory cell and molecular biology 2004, 31(4):395-404. 10.1165/rcmb.2004-0175OC, 15205180.
42. Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, Strieter RM. Ifn-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 1999, 163(10):5686-5692.
43. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, Peters-Golden M. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin e2 and to express cyclooxygenase-2. The Journal of clinical investigation 1995, 95(4):1861-1868. 10.1172/JCI117866, 295728, 7706493.
44. Charbeneau RP, Christensen PJ, Chrisman CJ, Paine R, Toews GB, Peters-Golden M, Moore BB. Impaired synthesis of prostaglandin e2 by lung fibroblasts and alveolar epithelial cells from gm-csf-/- mice: Implications for fibroproliferation. American journal of physiology 2003, 284(6):L1103-1111.
45. Hodges RJ, Jenkins RG, Wheeler-Jones CP, Copeman DM, Bottoms SE, Bellingan GJ, Nanthakumar CB, Laurent GJ, Hart SL, Foster ML, et al. Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin e(2) production. The American journal of pathology 2004, 165(5):1663-1676. 1618657, 15509536.